Avecho Biotechnology (ASX:AVE) starts dosing in topical CBD pain study

• Avecho (AVE) has commenced its Phase IIa Study examining a topical CBD gel for the management of pain associated with arthritis of the hand
• The study tests a proprietary formulation, developed by Avecho, incorporating its TPM technology
• This formulation has already been shown to increase the dermal absorption of CBD in laboratory experiments by five times
• The study’s high-level findings are expected in Q2 2022, with Avecho saying positive results would help the clinical development of a topical CBD product in the future
• Avecho Biotechnology (AVE) is trading at 1.2 cents just as the market opens

Avecho Biotechnology (AVE) has started patient dosing for its Phase IIa Study.

This study will look at examining whether topically applied cannabidiol (CBD) can provide relief from symptoms of osteoarthritis.

The proof-of-concept Th study is being led by Dr Daniel Lewis of the Daniel Lewis Rheumatology Centre, and co-investigator Professor Iain McGregor of the Lambert Initiative, an Australian research organisation for the discovery, development, and optimisation of safe cannabis medicines.

“Osteoarthritis (OA) is a chronic and poorly managed pain condition, with limited treatment options available. Increasingly, CBD is being prescribed for a range of pain conditions, despite a relative absence of formal human clinical trials demonstrating its effectiveness,” Avecho CEO Paul Gavin said.

“Commencement of patient dosing is an important milestone in our ongoing efforts to understand and quantify how it could help,” added Dr Gavin.

The study uses one of Avecho’s proprietary formulation vehicles incorporating its TPM technology. This formulation has already been shown to increase the dermal absorption of CBD in laboratory experiments by five times.

Fifteen patients with painful arthritis of the fingers or thumb have finished their baseline tests and are now starting therapy.

The topical formulation will be applied to painful joints of the fingers and/or thumb each day over a four-week period.

Assessment will include pain scores, functional scores, and assessments of grip strength using a dynamometer.

High-level results from the study are expected Q2 2022. Positive results would support the further clinical development of a topical CBD product.

The study’s high-level findings are expected in Q2 2022. The company said positive results would help the clinical development of a topical CBD product in the future.

Avecho Biotechnology (AVE) was trading at 1.2 cents just as the market opens.